Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Drug Enforcement Administration (DEA)
Pharma
DEA raises production quota on Takeda's Vyvanse and its generics
With a shortage of ADHD drugs persisting, the DEA has raised production limits on Takeda’s Vyvanse and its generic versions by 24%, the agency said.
Kevin Dunleavy
Sep 4, 2024 3:24pm
Sage, Biogen call an audible on pricing strategy for Zurzuvae
Nov 7, 2023 3:24pm
FDA, DEA urge production push to resolve stimulant shortages
Aug 3, 2023 8:05am
Idorsia requests to de-schedule DORA insomnia drugs
Apr 7, 2023 10:55am
